Better Therapeutics Inc. (BTTX): Skating on Thin Ice? We Know the Answer – News Heater
Home  »  Companies   »  Better Therapeutics Inc. (BTTX): Skating on Thin I...

Better Therapeutics Inc. (BTTX): Skating on Thin Ice? We Know the Answer

Better Therapeutics Inc. (NASDAQ:BTTX) went up by 23.49% from its latest closing price compared to the recent 1-year high of $29.40. The company’s stock price has collected 32.85% of gains in the last five trading sessions.

Is It Worth Investing in Better Therapeutics Inc. (NASDAQ :BTTX) Right Now?

Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for Better Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $17.00, which is $15.16 above the current price. BTTX currently public float of 10.63M and currently shorts hold a 9.54% ratio of that float. Today, the average trading volume of BTTX was 6.69M shares.

BTTX’s Market Performance

BTTX stocks went up by 32.85% for the week, with a monthly jump of 25.17% and a quarterly performance of -26.10%, while its annual performance rate touched -81.56%. The volatility ratio for the week stands at 14.65% while the volatility levels for the past 30 days are set at 19.32% for Better Therapeutics Inc. The simple moving average for the period of the last 20 days is 8.31% for BTTX stocks with a simple moving average of -63.98% for the last 200 days.

Analysts’ Opinion of BTTX

Many brokerage firms have already submitted their reports for BTTX stocks, with Chardan Capital Markets repeating the rating for BTTX by listing it as a “Buy.” The predicted price for BTTX in the upcoming period, according to Chardan Capital Markets is $17 based on the research report published on November 24th of the previous year 2021.

BTTX Trading at 12.78% from the 50-Day Moving Average

After a stumble in the market that brought BTTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.74% of loss for the given period.

Volatility was left at 19.32%, however, over the last 30 days, the volatility rate increased by 14.65%, as shares surge +42.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.36% lower at present.

During the last 5 trading sessions, BTTX rose by +32.85%, which changed the moving average for the period of 200-days by -81.54% in comparison to the 20-day moving average, which settled at $1.7263. In addition, Better Therapeutics Inc. saw -60.43% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BTTX starting from Armanino Andrew J., who purchase 15,000 shares at the price of $1.39 back on Jun 14. After this action, Armanino Andrew J. now owns 15,000 shares of Better Therapeutics Inc., valued at $20,846 using the latest closing price.

Parker Geoffrey M., the Director of Better Therapeutics Inc., purchase 25,000 shares at $1.45 during a trade that took place back on Jun 13, which means that Parker Geoffrey M. is holding 40,000 shares at $36,182 based on the most recent closing price.

Stock Fundamentals for BTTX

Equity return is now at value -113.60, with -96.40 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 9.56.

Is Everbridge Inc. (EVBG) a Keeper?

Everbridge Inc. (NASDAQ:EVBG) went down by -5.59% from its latest closing price compared to the recent 1-year high of $167.40. The company’s stock price has